Munich - Delayed Quote EUR
Elicera Therapeutics AB (8E8.MU)
0.3040
0.0000
(0.00%)
At close: April 24 at 8:03:38 AM GMT+2
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Expense
16,834.0560
16,834.0560
17,096.2770
19,362.7500
13,119.3690
Operating Income
-16,834.0560
-16,834.0560
-17,096.2770
-19,362.7500
-13,119.3690
Net Non Operating Interest Income Expense
773.7290
773.7290
698.3000
-75.8810
-1.0750
Pretax Income
-16,110.3270
-16,110.3270
-16,397.9770
-19,438.6310
-13,120.4430
Net Income Common Stockholders
-16,110.3270
-16,110.3270
-16,397.9770
-19,438.6310
-13,120.4430
Diluted NI Available to Com Stockholders
-16,110.3270
-16,110.3270
-16,397.9770
-19,438.6310
-13,120.4430
Basic EPS
-0.69
-0.51
-0.83
-0.98
-0.82
Diluted EPS
-0.69
-0.51
-0.83
-0.98
-0.82
Basic Average Shares
27,677.6750
31,588.8760
19,756.5990
19,835.3380
16,000.5400
Diluted Average Shares
35,093.2680
31,588.8760
19,756.5990
19,835.3380
16,000.5400
Total Operating Income as Reported
-16,884.0560
-16,884.0560
-17,096.2770
-19,362.7500
-13,119.3680
Total Expenses
16,834.0560
16,834.0560
17,096.2770
19,362.7500
13,119.3690
Net Income from Continuing & Discontinued Operation
-16,110.3270
-16,110.3270
-16,397.9770
-19,438.6310
-13,120.4430
Normalized Income
-16,110.3270
-16,110.3270
-16,397.9770
-19,438.6310
-13,120.4430
Interest Income
826.5260
826.5260
774.1890
53.4590
--
Interest Expense
52.7970
52.7970
75.8890
129.3400
1.0750
Net Interest Income
773.7290
773.7290
698.3000
-75.8810
-1.0750
EBIT
-16,057.5300
-16,057.5300
-16,322.0880
-19,309.2910
-13,119.3680
EBITDA
-16,045.7540
-16,045.7540
-16,310.3120
-19,297.4990
-13,107.5920
Reconciled Depreciation
11.7760
11.7760
11.7660
11.7920
11.7760
Net Income from Continuing Operation Net Minority Interest
-16,110.3270
-16,110.3270
-16,397.9770
-19,438.6310
-13,120.4430
Normalized EBITDA
-16,045.7540
-16,045.7540
-16,310.3120
-19,297.4990
-13,107.5920
12/31/2021 - 12/9/2021
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade